{"transactions":[{"id":4613529,"issuer":{"id":2671,"kind":"organization","name":"Protalix BioTherapeutics, Inc.","symbol":"PLX"},"owners":[{"id":55314,"kind":"person","name":"Schwartz Aharon","position":1,"cik":"0001625184","reported_name":"Schwartz Aharon","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2026-09-09T21:00:46.000Z","date":"2026-09-03","kind":"grant","planned":false,"acquired":true,"shares":8500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each restricted stock unit (RSU) represents the right to receive, following vesting, one share of the Isuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The shares of common stock underlying the RSUs vest in 12 equal quarterly installments commencing upon the date of grant."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The shares of common stock underlying the RSUs vest in 12 equal quarterly installments commencing upon the date of grant."}],"balance_after":8500,"derivative":{"underlying":"Common Stock","underlying_shares":8500},"source":{"system":"sec-edgar","filing":"0001178913-26-004471","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1625184/000117891326004471/ownership.xml","form_type":"4"}},{"id":4613528,"issuer":{"id":2671,"kind":"organization","name":"Protalix BioTherapeutics, Inc.","symbol":"PLX"},"owners":[{"id":55314,"kind":"person","name":"Schwartz Aharon","position":1,"cik":"0001625184","reported_name":"Schwartz Aharon","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (Right to Buy)","published_at":"2026-09-09T21:00:46.000Z","date":"2026-09-03","kind":"grant","planned":false,"acquired":true,"shares":17000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares of common stock underlying the stock options vest in 12 equal quarterly installments commencing upon the date of grant."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Does not include (i) options to purchase 40,000 shares of common stock at an exercise price equal to $3.55 per share that expire on January 20, 2030, (ii) options to purchase 50,000 shares of common stock at an exercise price equal to $1.03 per share that expire on September 7, 2032, (iii) options to purchase 61,676 shares of common stock at an exercise price equal to $1.66 per share that expire on September 29, 2033 and (iv) options to purchase 15,000 shares of common stock at an exercise price equal to $1.64 per share that expire on September 3, 2035."}],"balance_after":17000,"derivative":{"exercise_price":2.59,"expiration_date":"2036-09-03","underlying":"Common Stock","underlying_shares":17000},"source":{"system":"sec-edgar","filing":"0001178913-26-004471","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1625184/000117891326004471/ownership.xml","form_type":"4"}},{"id":1048610,"issuer":{"id":2671,"kind":"organization","name":"Protalix BioTherapeutics, Inc.","symbol":"PLX"},"owners":[{"id":55314,"kind":"person","name":"Schwartz Aharon","position":1,"cik":"0001625184","reported_name":"Schwartz Aharon","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (Right to Buy)","published_at":"2025-09-04T21:00:21.000Z","date":"2025-09-03","kind":"grant","planned":false,"acquired":true,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The shares of common stock underlying the stock options shall vest in 12 equal quarterly installments commencing upon the date of grant."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"Does not include (i) options to purchase 40,000 shares of common stock at an exercise price equal to $3.55 per share that expire on January 20, 2030, (ii) options to purchase 50,000 shares of common stock at an exercise price equal to $1.03 per share that expire on September 7, 2032 and (iii) options to purchase 61,676 shares of common stock at an exercise price equal to $1.66 per share that expire on September 29, 2033."}],"balance_after":15000,"derivative":{"exercise_price":1.64,"expiration_date":"2035-09-03","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001415889-25-023704","document":"form4-09042025_050909.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1006281/000141588925023704/form4-09042025_050909.xml","form_type":"4"}},{"id":1048609,"issuer":{"id":2671,"kind":"organization","name":"Protalix BioTherapeutics, Inc.","symbol":"PLX"},"owners":[{"id":55314,"kind":"person","name":"Schwartz Aharon","position":1,"cik":"0001625184","reported_name":"Schwartz Aharon","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-09-04T21:00:21.000Z","date":"2025-09-03","kind":"grant","planned":false,"acquired":true,"shares":7500,"ownership":{"direct":false,"nature":"By Trust"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents restricted shares of common stock awarded to the Reporting Person under the Amended and Restated Protalix BioTherapeutics, Inc. 2006 Stock Incentive Plan, as amended (the \"Plan\"). The restricted shares vest in 12 equal quarterly installments commencing upon the date of grant."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"To qualify for certain tax benefits under Section 102 of the Israeli Tax Ordinance, securities issued under the Plan must be registered in the name of a trustee."}],"balance_after":7500,"source":{"system":"sec-edgar","filing":"0001415889-25-023704","document":"form4-09042025_050909.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1006281/000141588925023704/form4-09042025_050909.xml","form_type":"4"}},{"id":1069331,"issuer":{"id":2671,"kind":"organization","name":"Protalix BioTherapeutics, Inc.","symbol":"PLX"},"owners":[{"id":55314,"kind":"person","name":"Schwartz Aharon","position":1,"cik":"0001625184","reported_name":"Schwartz Aharon","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-08-12T20:30:07.000Z","date":"2025-06-10","kind":"purchase","planned":false,"acquired":true,"shares":129000,"price":1.596,"value":205884.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"This transaction was executed in multiple trades at prices ranging from $1.60 to $1.575 per share. The price reported above reflects the weighted average purchase price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected."}],"balance_after":303000,"source":{"system":"sec-edgar","filing":"0001415889-25-021494","document":"form4-08122025_040801.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1006281/000141588925021494/form4-08122025_040801.xml","form_type":"4"}},{"id":1768751,"issuer":{"id":2671,"kind":"organization","name":"Protalix BioTherapeutics, Inc.","symbol":"PLX"},"owners":[{"id":55314,"kind":"person","name":"Schwartz Aharon","position":1,"cik":"0001625184","reported_name":"Schwartz Aharon","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-10-03T21:00:32.000Z","date":"2023-09-29","kind":"grant","planned":false,"acquired":true,"shares":61676,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares of common stock underlying the stock options shall vest in 12 equal quarterly installments commencing upon the date of grant.  The stock options are subject to accelerated vesting upon a corporate transaction or a change in control as described in the Protalix BioTherapeutics, Inc., Amended and Restated 2006 Stock Incentive Plan, as amended."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Does not include (i) options to purchase 40,000 shares of common stock at an exercise price equal to $3.55 per share that expire on January 20, 2030 and (ii) options to purchase 50,000 shares of common stock at an exercise price equal to $1.03 per share that expire on September 7, 2032."}],"balance_after":61676,"derivative":{"exercise_price":1.66,"expiration_date":"2033-09-29","underlying":"Common Stock","underlying_shares":61676},"source":{"system":"sec-edgar","filing":"0001415889-23-013900","document":"form4-10032023_051021.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1006281/000141588923013900/form4-10032023_051021.xml","form_type":"4"}},{"id":2063872,"issuer":{"id":2671,"kind":"organization","name":"Protalix BioTherapeutics, Inc.","symbol":"PLX"},"owners":[{"id":55314,"kind":"person","name":"Schwartz Aharon","position":1,"cik":"0001625184","reported_name":"Schwartz Aharon","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-01-05T22:08:38.000Z","date":"2023-01-03","kind":"purchase","acquired":true,"shares":110000,"price":1.4165,"value":155815.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"This transaction was executed in multiple trades at prices ranging from $1.430 to $1.405 per share. The price reported above reflects the weighted average purchase price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected."}],"balance_after":174000,"source":{"system":"sec-edgar","filing":"0001104659-23-001495","document":"tm232297-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1006281/000110465923001495/tm232297-1_4seq1.xml","form_type":"4"}},{"id":2162617,"issuer":{"id":2671,"kind":"organization","name":"Protalix BioTherapeutics, Inc.","symbol":"PLX"},"owners":[{"id":55314,"kind":"person","name":"Schwartz Aharon","position":1,"cik":"0001625184","reported_name":"Schwartz Aharon","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (Right to Buy)","published_at":"2022-09-09T21:02:10.000Z","date":"2022-09-07","kind":"grant","acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares of common stock underlying the stock options shall vest in 16 equal quarterly installments commencing upon the date of grant. The stock options are subject to accelerated vesting upon a corporate transaction or a change in control as described in the Protalix BioTherapeutics, Inc., Amended and Restated 2006 Stock Incentive Plan, as amended."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Does not include options to purchase 40,000 shares of common stock at an exercise price equal to $3.55 per share that expire on January 20, 2030."}],"balance_after":50000,"derivative":{"exercise_price":1.03,"expiration_date":"2032-09-07","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001104659-22-098948","document":"tm2225460-5_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1006281/000110465922098948/tm2225460-5_4seq1.xml","form_type":"4"}},{"id":3178191,"issuer":{"id":2671,"kind":"organization","name":"Protalix BioTherapeutics, Inc.","symbol":"PLX"},"owners":[{"id":55314,"kind":"person","name":"Schwartz Aharon","position":1,"cik":"0001625184","reported_name":"Schwartz Aharon","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-04-13T20:05:23.000Z","date":"2020-04-07","kind":"purchase","acquired":true,"shares":64000,"price":2.426,"value":155264.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"This transaction was executed in multiple trades at prices ranging from $2.39 to $2.53. The price reported above reflects the weighted average purchase price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected."}],"balance_after":64000,"source":{"system":"sec-edgar","filing":"0001104659-20-045926","document":"tm2015785d1_4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1006281/000110465920045926/tm2015785d1_4.xml","form_type":"4"}},{"id":3215010,"issuer":{"id":150527,"kind":"organization","name":"Foamix Pharmaceuticals Ltd.","symbol":"FOMX"},"owners":[{"id":55314,"kind":"person","name":"Schwartz Aharon","position":1,"cik":"0001625184","reported_name":"Schwartz Aharon","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Options","published_at":"2020-03-11T17:40:20.000Z","date":"2020-03-09","kind":"disposition_to_issuer","acquired":false,"shares":38156,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"At the Effective Time, each option to purchase a Foamix Share (a \"Foamix Option\") was converted into an option to purchase Menlo Common Stock (an \"Adjusted Option\") with the same terms and conditions as applied to the Foamix Option immediately prior to the Effective Time; however, the Adjusted Option covers a number of shares of Menlo Common Stock equal to the product of (i) the number of Foamix Shares subject to the Foamix Option immediately prior to the Effective Time and (ii) the Exchange Ratio, and has an exercise price per share equal to the quotient of (i) the exercise price per Foamix Share subject to such Foamix Option immediately prior to the Effective Time divided by (ii) the Exchange Ratio. If the CSRs become convertible, then the Menlo board of directors will make equitable adjustments to the exercise price per share of and the number of shares of Menlo Common Stock that are subject to Adjusted Options."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"The ordinary shares underlying these options vest over a 12 month period, in equal, quarterly installments, ending February 27, 2021."}],"balance_after":0,"derivative":{"exercise_price":3.53,"expiration_date":"2030-02-27","underlying":"Ordinary Shares","underlying_shares":38156},"source":{"system":"sec-edgar","filing":"0001209191-20-018199","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1606645/000120919120018199/doc4.xml","form_type":"4"}},{"id":3215009,"issuer":{"id":150527,"kind":"organization","name":"Foamix Pharmaceuticals Ltd.","symbol":"FOMX"},"owners":[{"id":55314,"kind":"person","name":"Schwartz Aharon","position":1,"cik":"0001625184","reported_name":"Schwartz Aharon","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Options","published_at":"2020-03-11T17:40:20.000Z","date":"2020-03-09","kind":"disposition_to_issuer","acquired":false,"shares":49412,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"At the Effective Time, each option to purchase a Foamix Share (a \"Foamix Option\") was converted into an option to purchase Menlo Common Stock (an \"Adjusted Option\") with the same terms and conditions as applied to the Foamix Option immediately prior to the Effective Time; however, the Adjusted Option covers a number of shares of Menlo Common Stock equal to the product of (i) the number of Foamix Shares subject to the Foamix Option immediately prior to the Effective Time and (ii) the Exchange Ratio, and has an exercise price per share equal to the quotient of (i) the exercise price per Foamix Share subject to such Foamix Option immediately prior to the Effective Time divided by (ii) the Exchange Ratio. If the CSRs become convertible, then the Menlo board of directors will make equitable adjustments to the exercise price per share of and the number of shares of Menlo Common Stock that are subject to Adjusted Options."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"The ordinary shares underlying these options vest over a 12 month period, in equal, quarterly installments, ending May 16, 2020."}],"balance_after":0,"derivative":{"exercise_price":2.66,"expiration_date":"2029-05-16","underlying":"Ordinary Shares","underlying_shares":49412},"source":{"system":"sec-edgar","filing":"0001209191-20-018199","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1606645/000120919120018199/doc4.xml","form_type":"4"}},{"id":3215008,"issuer":{"id":150527,"kind":"organization","name":"Foamix Pharmaceuticals Ltd.","symbol":"FOMX"},"owners":[{"id":55314,"kind":"person","name":"Schwartz Aharon","position":1,"cik":"0001625184","reported_name":"Schwartz Aharon","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Options","published_at":"2020-03-11T17:40:20.000Z","date":"2020-03-09","kind":"disposition_to_issuer","acquired":false,"shares":24883,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"At the Effective Time, each option to purchase a Foamix Share (a \"Foamix Option\") was converted into an option to purchase Menlo Common Stock (an \"Adjusted Option\") with the same terms and conditions as applied to the Foamix Option immediately prior to the Effective Time; however, the Adjusted Option covers a number of shares of Menlo Common Stock equal to the product of (i) the number of Foamix Shares subject to the Foamix Option immediately prior to the Effective Time and (ii) the Exchange Ratio, and has an exercise price per share equal to the quotient of (i) the exercise price per Foamix Share subject to such Foamix Option immediately prior to the Effective Time divided by (ii) the Exchange Ratio. If the CSRs become convertible, then the Menlo board of directors will make equitable adjustments to the exercise price per share of and the number of shares of Menlo Common Stock that are subject to Adjusted Options."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The ordinary shares underlying these options vested over a 12 month period, in equal, quarterly installments, ending May 8, 2019."}],"balance_after":0,"derivative":{"exercise_price":5.022,"expiration_date":"2028-05-08","underlying":"Ordinary Shares","underlying_shares":24883},"source":{"system":"sec-edgar","filing":"0001209191-20-018199","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1606645/000120919120018199/doc4.xml","form_type":"4"}},{"id":3215007,"issuer":{"id":150527,"kind":"organization","name":"Foamix Pharmaceuticals Ltd.","symbol":"FOMX"},"owners":[{"id":55314,"kind":"person","name":"Schwartz Aharon","position":1,"cik":"0001625184","reported_name":"Schwartz Aharon","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Options","published_at":"2020-03-11T17:40:20.000Z","date":"2020-03-09","kind":"disposition_to_issuer","acquired":false,"shares":21435,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"At the Effective Time, each option to purchase a Foamix Share (a \"Foamix Option\") was converted into an option to purchase Menlo Common Stock (an \"Adjusted Option\") with the same terms and conditions as applied to the Foamix Option immediately prior to the Effective Time; however, the Adjusted Option covers a number of shares of Menlo Common Stock equal to the product of (i) the number of Foamix Shares subject to the Foamix Option immediately prior to the Effective Time and (ii) the Exchange Ratio, and has an exercise price per share equal to the quotient of (i) the exercise price per Foamix Share subject to such Foamix Option immediately prior to the Effective Time divided by (ii) the Exchange Ratio. If the CSRs become convertible, then the Menlo board of directors will make equitable adjustments to the exercise price per share of and the number of shares of Menlo Common Stock that are subject to Adjusted Options."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The ordinary shares underlying this option vest over a period of four years (25% on July 13, 2017 and 6.25% every three months thereafter) ending July 13, 2021."}],"balance_after":0,"derivative":{"exercise_price":4.687,"expiration_date":"2027-07-13","underlying":"Ordinary Shares","underlying_shares":21435},"source":{"system":"sec-edgar","filing":"0001209191-20-018199","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1606645/000120919120018199/doc4.xml","form_type":"4"}},{"id":3215006,"issuer":{"id":150527,"kind":"organization","name":"Foamix Pharmaceuticals Ltd.","symbol":"FOMX"},"owners":[{"id":55314,"kind":"person","name":"Schwartz Aharon","position":1,"cik":"0001625184","reported_name":"Schwartz Aharon","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Options","published_at":"2020-03-11T17:40:20.000Z","date":"2020-03-09","kind":"disposition_to_issuer","acquired":false,"shares":24000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"At the Effective Time, each option to purchase a Foamix Share (a \"Foamix Option\") was converted into an option to purchase Menlo Common Stock (an \"Adjusted Option\") with the same terms and conditions as applied to the Foamix Option immediately prior to the Effective Time; however, the Adjusted Option covers a number of shares of Menlo Common Stock equal to the product of (i) the number of Foamix Shares subject to the Foamix Option immediately prior to the Effective Time and (ii) the Exchange Ratio, and has an exercise price per share equal to the quotient of (i) the exercise price per Foamix Share subject to such Foamix Option immediately prior to the Effective Time divided by (ii) the Exchange Ratio. If the CSRs become convertible, then the Menlo board of directors will make equitable adjustments to the exercise price per share of and the number of shares of Menlo Common Stock that are subject to Adjusted Options."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The Options vested over a period of three years from June 22, 2015 (33.3% on each anniversary of such date)."}],"balance_after":0,"derivative":{"exercise_price":11.8687,"expiration_date":"2025-06-22","underlying":"Ordinary Shares","underlying_shares":24000},"source":{"system":"sec-edgar","filing":"0001209191-20-018199","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1606645/000120919120018199/doc4.xml","form_type":"4"}},{"id":3215005,"issuer":{"id":150527,"kind":"organization","name":"Foamix Pharmaceuticals Ltd.","symbol":"FOMX"},"owners":[{"id":55314,"kind":"person","name":"Schwartz Aharon","position":1,"cik":"0001625184","reported_name":"Schwartz Aharon","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares","published_at":"2020-03-11T17:40:20.000Z","date":"2020-03-09","kind":"disposition_to_issuer","acquired":false,"shares":112200,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On March 9, 2020 (the \"Closing Date\"), pursuant to the Agreement and Plan of Merger, dated as of November 10, 2019, as amended on December 4, 2019 (as amended, the \"Merger Agreement\"), by and among Menlo Therapeutics Inc., a Delaware corporation (\"Menlo\"), Foamix Pharmaceuticals Ltd., a company organized under the laws of Israel (\"Foamix\"), and Giants Merger Subsidiary Ltd., a direct, wholly owned subsidiary of Menlo (\"Merger Sub\"), Merger Sub merged with and into Foamix, with Foamix surviving as a wholly owned subsidiary of Menlo (the \"Merger\"). At the effective time of the Merger (the \"Effective Time\"), each ordinary share, par value NIS 0.16 per share, of Foamix (\"Foamix Shares\") issued and outstanding immediately prior to the Effective Time was deemed transferred under Israeli law to Menlo in exchange for the right to receive (i) 0.5924 shares (the \"Exchange Ratio\") of common stock of Menlo (\"Menlo Common Stock\") and (ii) one contingent stock right (continued in footnote 2)"},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"(a \"CSR\"; and collectively, the \"CSRs\") which are subject to the terms and conditions of the contingent stock rights agreement, dated as of March 9, 2020, by and between American Stock Transfer & Trust Company, LLC and Menlo (the \"CSR Agreement\"), as further described in that Current Report on Form 8-K filed by Menlo with the Securities and Exchange Commission on March 9, 2020 (collectively, the \"Merger Consideration\"). The closing price of a share of Menlo Common Stock on March 6, 2020, the last trading day before the Effective Time, was $4.15. No fractional share of Menlo Common Stock was issued in the Merger, and Foamix shareholders received cash in lieu of fractional shares, as specified in the Merger Agreement."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001209191-20-018199","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1606645/000120919120018199/doc4.xml","form_type":"4"}},{"id":3230632,"issuer":{"id":150527,"kind":"organization","name":"Foamix Pharmaceuticals Ltd.","symbol":"FOMX"},"owners":[{"id":55314,"kind":"person","name":"Schwartz Aharon","position":1,"cik":"0001625184","reported_name":"Schwartz Aharon","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Options","published_at":"2020-03-03T16:33:20.000Z","date":"2020-02-27","kind":"grant","acquired":true,"shares":38156,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Each option represents a contingent right to purchase one ordinary share of the issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The ordinary shares underlying this option award vest over a 12 month period, in equal, quarterly installments, ending February 27, 2021."}],"balance_after":38156,"derivative":{"exercise_price":3.53,"expiration_date":"2030-02-27","underlying":"Ordinary Shares","underlying_shares":38156},"source":{"system":"sec-edgar","filing":"0001209191-20-015201","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1606645/000120919120015201/doc4.xml","form_type":"4"}},{"id":3305488,"issuer":{"id":2671,"kind":"organization","name":"Protalix BioTherapeutics, Inc.","symbol":"PLX"},"owners":[{"id":55314,"kind":"person","name":"Schwartz Aharon","position":1,"cik":"0001625184","reported_name":"Schwartz Aharon","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (Right to Buy)","published_at":"2020-01-22T22:02:42.000Z","date":"2020-01-20","kind":"grant","acquired":true,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares of common stock underlying the stock options shall vest in 16 equal quarterly installments commencing upon the date of grant. The stock options are subject to accelerated vesting upon a corporate transaction or a change in control as described in the Protalix BioTherapeutics, Inc., 2006 Stock Incentive Plan, as amended."}],"balance_after":40000,"derivative":{"exercise_price":3.55,"expiration_date":"2030-01-20","underlying":"Common Stock","underlying_shares":40000},"source":{"system":"sec-edgar","filing":"0001104659-20-005970","document":"tm205452-4_4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1006281/000110465920005970/tm205452-4_4.xml","form_type":"4"}},{"id":3518002,"issuer":{"id":150527,"kind":"organization","name":"Foamix Pharmaceuticals Ltd.","symbol":"FOMX"},"owners":[{"id":55314,"kind":"person","name":"Schwartz Aharon","position":1,"cik":"0001625184","reported_name":"Schwartz Aharon","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Options","published_at":"2019-05-20T18:36:52.000Z","date":"2019-05-16","kind":"grant","acquired":true,"shares":49412,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Each option represents a contingent right to purchase one ordinary share of the issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The ordinary shares underlying these options vest over a 12 month period, in equal, quarterly installments, ending May 16, 2020."}],"balance_after":49412,"derivative":{"exercise_price":2.66,"expiration_date":"2029-05-16","underlying":"Ordinary Shares","underlying_shares":49412},"source":{"system":"sec-edgar","filing":"0001209191-19-031532","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1606645/000120919119031532/doc4.xml","form_type":"4"}},{"id":3740694,"issuer":{"id":150527,"kind":"organization","name":"Foamix Pharmaceuticals Ltd.","symbol":"FOMX"},"owners":[{"id":55314,"kind":"person","name":"Schwartz Aharon","position":1,"cik":"0001625184","reported_name":"Schwartz Aharon","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares","published_at":"2018-12-06T06:09:21.000Z","date":"2018-11-28","kind":"purchase","acquired":true,"shares":12200,"price":3.883,"value":47372.6,"ownership":{"direct":true},"balance_after":112200,"source":{"system":"sec-edgar","filing":"0001178913-18-003093","document":"zk1822353.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1606645/000117891318003093/zk1822353.xml","form_type":"4"}},{"id":3740693,"issuer":{"id":150527,"kind":"organization","name":"Foamix Pharmaceuticals Ltd.","symbol":"FOMX"},"owners":[{"id":55314,"kind":"person","name":"Schwartz Aharon","position":1,"cik":"0001625184","reported_name":"Schwartz Aharon","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares","published_at":"2018-12-06T06:09:21.000Z","date":"2018-11-27","kind":"purchase","acquired":true,"shares":50000,"price":3.916,"value":195800.0,"ownership":{"direct":true},"balance_after":100000,"source":{"system":"sec-edgar","filing":"0001178913-18-003093","document":"zk1822353.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1606645/000117891318003093/zk1822353.xml","form_type":"4"}},{"id":3740692,"issuer":{"id":150527,"kind":"organization","name":"Foamix Pharmaceuticals Ltd.","symbol":"FOMX"},"owners":[{"id":55314,"kind":"person","name":"Schwartz Aharon","position":1,"cik":"0001625184","reported_name":"Schwartz Aharon","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares","published_at":"2018-12-06T06:09:21.000Z","date":"2018-11-26","kind":"purchase","acquired":true,"shares":50000,"price":3.892,"value":194600.0,"ownership":{"direct":true},"balance_after":50000,"source":{"system":"sec-edgar","filing":"0001178913-18-003093","document":"zk1822353.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1606645/000117891318003093/zk1822353.xml","form_type":"4"}},{"id":3938344,"issuer":{"id":150527,"kind":"organization","name":"Foamix Pharmaceuticals Ltd.","symbol":"FOMX"},"owners":[{"id":55314,"kind":"person","name":"Schwartz Aharon","position":1,"cik":"0001625184","reported_name":"Schwartz Aharon","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Options","published_at":"2018-05-10T17:24:46.000Z","date":"2018-05-08","kind":"grant","acquired":true,"shares":24883,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Each option represents a contingent right to purchase one ordinary share of the issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The ordinary shares underlying these options vest over a 12 month period, in equal, quarterly installments, ending May 8, 2019."}],"balance_after":24883,"derivative":{"exercise_price":5.02,"expiration_date":"2028-05-08","underlying":"Ordinary Shares","underlying_shares":24883},"source":{"system":"sec-edgar","filing":"0001178913-18-001594","document":"zk1821659.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1606645/000117891318001594/zk1821659.xml","form_type":"4"}}]}